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Background: Catheter-related infections (CRIs) caused by peripheral intravenous catheters
(PIVCs) are an increasingly common iatrogenic complication. To prevent this, recommended
timelines for routine replacementof PIVCs have increased from48 h to 72 hand subsequently
to 96 h, despite a lack of supporting scientific evidence.
Aim: To compare closed-system (COS) PIVCs with open-system (MOS) PIVCs.
Methods: This prospective, randomized controlled trial compared the indwell time of COS
PIVCs without complications with that of MOS PIVCs, removed only by clinical indication. In
total, 1199 PIVCs (642 inpatients) were randomized and 283 PIVCs were cultured. Sixteen
catheters (11 patients) were lost to the study after randomization.
Findings: In total, 104,469 catheter-hours (54,173 h in 584 COS and 50,296 h in 599 MOS)
were recorded. The median dwell time was 137.1 h for COS PIVCs and 96 h for MOS PIVCs
(P¼ 0.001). Among PIVCs in place for24 h, themedian dwell timewas 144.5 h for COSPIVCs
[95% confidence interval (CI) 123.4e165.6] and 99 h for MOS PIVCs (95% CI 87.2e110.8). Use
of COS PIVCs reduced phlebitis rates by 29% (31 vs 45 cases/1000 catheter-days; P¼ 0.004).
The probability that a MOS PIVCwould last for 96 h was 79.9%, and the probability that a COS
PIVC would last for 144 h was 80.4%. There were no significant differences in rates of bac-
terial colonization per 1000 catheter-days (51.1 COS vs 54.1 MOS) or CRI (5.76 COS vs 6.65
MOS). Nevertheless, there was a 20% relative risk reduction in CRI.
Conclusion: Use of COS PIVCs reduced episodes of phlebitis and risk of infection at a cost
of only V0.09/day. When PIVCs are replaced based on clinical indication, COS PIVCs last
for up to 144 h and MOS PIVCs last for up to 96 h without increased risk and with significant
cost savings (V786,257/year/1000 beds).
ª 2013 The Authors. Published by Elsevier Ltd on behalf of the Healthcare Infection
Society. Open access under CC BY license.coSanCarlos,C/ProfesorMartı´nLagos s/n,28040Madrid,Spain.Tel.:þ34913303000; fax:þ34913303062.
drid.org (J.L. Gonza´lez Lo´pez).
Elsevier Ltd on behalf of the Healthcare Infection Society.  Open access under CC BY license.
J.L. Gonza´lez Lo´pez et al. / Journal of Hospital Infection 86 (2014) 117e126118Introduction days between March and July 2008. The 126 nurses whoPeripheral intravenous catheters (PIVCs) are the most
commonly used invasive devices (150 million/year in the USA).1
In Spain, nearly 50% of inpatients receive an intravenous
catheter, almost 95% of which are peripheral. PIVCs have been
recognized as a source of Staphylococcus aureus bacteraemia
in 12e50% of all catheter-related bloodstream infections
(CRBSI),2,3 and are the cause of considerable morbidity and
mortality, prolonged hospital stay and an increased cost4,5 of
up to V3700 per episode.6
It has been reported that nearly half of PIVC-related bac-
teraemias are associated with phlebitis,3,7 which is the most
important complication of PIVCs4 (approximately 20% of
patients).7e9
Catheter-related complication (CRC) rates are thought to be
associatedwith the lengthof time that thecatheter remains in the
vein (indwell time). The timelines for routine replacement have
been the subject of controversy and uncertainty. Over the years,
they have increased from 48 h to 72 h10,11 and, most recently, to
96 h.12 However, such recommendations are based primarily on
dated studies (1975,10 198711 and 199812) that did not take recent
manufacturing changes in PIVC technology into account.
Safety PIVCs, which reduce the risk of sharps injury, have
been introduced recently. Needleless connectors create
‘closed systems’ that have lower rates of microbial contami-
nation compared with three-way ‘stopcocks’.13,14 However,
safety devices cost more than conventional devices, and ‘in-
tegrated closed devices’15 cost even more than open ones. To
the authors’ knowledge, this is the first study to compare open
and closed safety PIVCs.
Methods
Objectives and definitions
The COSMOS study was a randomized controlled trial to
investigate the clinical performance of two state-of-the-art
safety PIVC systems: a ‘compact’ closed system (COS) and a
‘mounted’ open system (MOS), both of which should only be
removed from patients when clinically indicated. The two sys-
temswere compared in termsof effectiveness (insertion success,
maintenance, utility), efficacy (indwell time without complica-
tions), safety for professionals and patients against accidental
needlestick injury or CRC rates (phlebitis, pain, painful haema-
toma, infiltration/extravasation, occlusion, bacterial coloniza-
tion, suspicion of infection by unexplained fever, catheter-
related infection) and efficiency (cost analysis).
Catheter-related infection (CRI) was defined as the growth
of more than 15 colony-forming units of the same species in
semiquantitative culture of catheter tips removed as a result of
phlebitis, pain or the suspicion of infection due to unexplained
fever, or by defervescence within 24 h of catheter
removal.5,16,17
Study design and sample
This prospective, open label, parallel-group randomized
control trial was conducted in three medical (61 beds) and
surgical (154 beds) wards at the Hospital Clı´nico ‘San Carlos’, a
1000-bed tertiary university hospital in Madrid, Spain, for 108comprised the staff of the three wards participated as field
researchers. PIVCs were inserted and maintained in accor-
dance with the guidelines of the US Centers for Disease Control
and Prevention (CDC),5 except for routine replacement reco-
mmendations (i.e. catheters were only removed when clini-
cally indicated). The needleless connector was replaced
routinely every eight days (after up to 64 activations), which is
less than the 70 activations reported by Adams et al.18
All patients aged 18 years needing a PIVC for at least 24 h
were evaluated for inclusion in the study. Informed consent
was obtained and enrolled patients were randomized into the
COS or MOS PIVC group. Patients were excluded if they were
participating in another study, had a PIVC placed under
emergency conditions, had a synchronous catheter (PIVC,
intravenous midline, peripherally inserted central catheter or
central venous catheter) or had a fever of 38 C.
The sample size was calculated on the assumption of a
phlebitis rate of 15% in the MOS group at 72 h, a 5% reduction in
the COS group, alpha error of 0.045 and beta error of 0.20.
Phlebitis was chosen as the endpoint because it is the most
common complication associated with CRI and PIVC removal.4,5
The minimum calculated accrual number was 435 catheters in
each arm of the study.
After the first 420 patients were enrolled, an interim
analysis revealed that nurses had been less familiar with COS
PIVCs than MOS PIVCs at study initiation (17.2% vs 82.8% of
nurses; respectively), because MOS PIVCs had been used in the
hospital for years while COS PIVCs had only been introduced
recently. This led the investigators to increase the target
sample size to 1200 catheters so that the learning curve would
have no impact on clinical outcomes.
At least 141 catheters from each group were selected at
random and cultured to determine baseline colonization rates.
This sample size assumed a 9.5% rate of catheter contamina-
tion17 with a 95% confidence level and a false-positive sample
error rate of 3%. The size of the sample was adequate to detect
a difference in the frequency of colonization between the
systems of 10%, with an alpha error of 0.05 and a power of 80%
(beta error 0.20). Catheters were evaluated using Maki’s
semiquantitative culture technique.16 Laboratory technicians
and microbiologists who cultured the catheter tips were
blinded to the study group assignment.
Randomization was computer generated.19 Study variables
and their definitions have been described elsewhere.20Materials
The COS PIVC (Figure 1) used in this study was the Nexiva
closed intravenous catheter system with a Q-Syte luer access
split-septum connector (BD, Franklin Lakes, NJ, USA). The
catheter is made of Vialon (a proprietary polyurethane) with
integrated extension tubing, a stabilization platform (wings)
and a passive needle shielding mechanism. A second Q-Syte
was added in order to close the Y-connector completely.
The MOS PIVC (Figure 1) used in this study was the Vasocan
safety catheter (B. Braun, Melsungen, Germany), made of
polytetrafluoroethylene (PTFE). This catheter has wings and a
passive safety mechanism. A three-way tap (‘stopcock’) with
10 cm of extension tubing (BD Connecta) with a luer/luer-lock
Sollner cap (Amebil, Basauri, Spain) was added.
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Paul, MN, USA) was used for both groups. Following the manu-
facturer’s recommendations, dressings were changed every
seven days, or sooner if necessary. Seventy percent alcohol was
used for skin antisepsis and disinfection of access ports.
Statistical analysis
It was hypothesized that, for the intention-to-treat (ITT)
population, the COS groupwould have a 5% reduction in efficacy
and safety compared with the MOS group. Qualitative variables
were compared using Chi-squared or Fisher’s exact tests.
Quantitative variables were analysed using Student’s t-test.
The rate of events was calculated in relation to catheter-
hours and catheter-days. This analysis was performed using
KaplaneMeier survival curves to allow for intra-individual
variability in patients who were randomized to more than
one catheter. The conditional hazard ratio was determined
using Cox’s proportional hazards regression by generalized
estimation equation models, both univariate and with adjusted
analysis for confounding variables.
Statistical analysis was performed using the ITT population,
which included all catheters, and the ‘modified’ ITTFigure 1. Composition of the closed and openpopulation, which included catheters with at least one
assessment (i.e. in place for 24 h). This parameter takes into
account the fact that many catheters are inserted for brief
periods of time, and are removed for reasons unrelated to
catheter performance or complications.
In all analyses, the level of statistical significance was
assumed to be 0.05. The post-hoc power of the study was 97%
(Granmo 7.11: Program to calculate the sample size and power
of contrast hypothesis. Consortion URLEC, Institut Hospital del
Mar d’Investigacions Me´diques, Barcelona, Spain).
Cost analysis
Primary direct cost calculations were based on 20 min of
nursing time for insertion, as measured at the study centre and
supported by similar studies,21,22 plus the cost of materials
used in the insertion and maintenance of catheters with a daily
saline flushing. These calculations allow the extrapolation of
potential savings. The material costs are those paid by the
hospital in 2012, according to its accounting system.
The trial protocol is reported in accordance with the CON-
SORT 2010 statement,23 and is registered on ClinicalTrials.gov
(NCT00665886). All statistical analyses were undertaken usingsystem peripheral intravenous catheters.
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Inc, Chicago, IL, USA) and Data Analysis and Statistical Soft-
ware Version 9.0 (Stata Corp., College Station, TX, USA).Results
Of 1294 catheters evaluated in 694 inpatients, 95 PIVCs in 52
patients were considered ineligible. After early loss of 16
PIVCs, the ITT population was composed of 1183 catheters (631
inpatients), and the modified ITT population was composed of
952 catheters (513 patients). With a mean age of 71.5 years,
patients were similar in both groups in terms of sex, race, hy-
pertension, obesity, diabetes and mortality (P ¼ not signifi-
cant); the only significant difference was morbid obesity
(P ¼ 0.006). All analyses were controlled for this parameter
(conditional Cox model) and the outcome measures were not
affected. In addition, there were no differences between the
groups in terms of the presence of surgical wounds and drains,
urinary catheters, frequency of healthy vein or repeated
punctures, gauge or length of catheter, frequency of insertion
site (hand/forearm), use of the right vs left arm, or specific
vein cannulated (basilic/cephalic/median-cubital).
Both systems were analysed by insertion success (Table I),
and all catheters with a successful or failed insertion were
included in the ITT analysis. MOS PIVCs were significantly more
likely to be inserted with fewer attempts (P¼ 0.001) due to the
previous experience of nurses with this system. There were no
significant differences relative to catheter use.When evaluated
by number of patient exposure-days to each type of intravenous
infusion listed in Table I (antibiotics, chemotherapy, lipids),
there was no difference between the two groups. However,
there was a difference in the use of infusion pumps (6% COS vs
3.5% MOS; P ¼ 0.049), which is considered a risk factor for the
occurrence of phlebitis24 and CRI.25Indwell times
In total, 104,469 catheter-hours (54,173 hours in 584 COS
PIVCs and 50,296 hours in 599 MOS PIVCs) were recorded. The
maximum indwell time was 40.5 days in a patient with a COS
PIVC.
The mean and median dwell times in the ITT population
were 206.4 h and 114.3 h, respectively. The large difference
between these values is due to the broad range of dwell times
(0e972 h). As shown in Table II, the median time to any adverse
event was significantly higher for the COS group than the MOS
group (P ¼ 0.003).
Survival curves until the onset of CRC for both groups are
shown in Figure 2. The curves begin to separate between 24 and
48 h, and remain separated beyond 240 h at a statistically sig-
nificant level (P ¼ 0.001). When these results are adjusted for
morbid obesity, the outcomes are unchanged [adjusted con-
ditional hazard ratio 0.752; 95% confidence interval (CI)
0.635e0.891]. Use of COS PIVCs provides a relative risk
reduction (RRR) of 25% of CRC in the ITT population. At 120 h,
the number needed to treat is 8.3, meaning that one catheter-
related complication is avoided for every eight COS PIVCs used.
Figure 3 shows the stratified analysis of the main effect of CRC
in categories of baseline variables.
For the catheters that remained in place for24 h (Table II),
the median dwell time was 144.5 h for COS PIVCs, whichprovides a RRR of 29% of CRC compared with MOS PIVCs (con-
ditional hazard ratio 0.707; 95% CI 0.590e0.848; P < 0.001)
with a number needed to treat at 144 h (sixth day) of 9.4.
Complication rates
Reasons for catheter removal are summarized in Table I.
There were 70 cases of phlebitis in the COS group (12%, 31
cases/1000 catheter-days) compared with 101 cases in the MOS
group (16.9%, 45 cases/1000 catheter-days). Use of COS PIVCs
led to a reduction in the phlebitis rate of 29% (P ¼ 0.004).
Table III presents the CRC rates according to their frequency
per 1000 catheter-hours and catheter-days, showing a signifi-
cant reduction in the rate of phlebitis (grade 2 or higher, 36%),
CRC (25%) and infiltration (24%) in the COS group, associated
with RRR for painful haematoma (49%), occlusion (24%), pain
(22%) and CRI (20%). However, there was no significant diffe-
rence in the cumulative incidence (22.6% COS vs 21.3% MOS) or
in the incidence density rates per 1000 catheter-days (51.1 COS
vs 54.1 MOS) for bacterial colonization, and no statistical sig-
nificance could be found between the CRI rates of the COS
(2.2%) and MOS (2.5%) groups.
In this study, Staphylococcus epidermidis was responsible
for 45.7% of colonization and 52.4% of CRI. S. aureus was iso-
lated in two of 21 cases of CRI (9.5%), one in each study arm.
Although more cases of bacterial colonization were detected in
the COS group (n¼ 37) than in the MOS group (n¼ 33), only nine
cases of CRI were confirmed in the COS group, compared with
12 cases in the MOS group.
Finally, no needlestick injuries occurred to healthcare
workers in either group, proving that both MOS and COS PIVCs
are passive safety devices.
Cost analysis
The cost analysis is summarized in Table IV. Using the costs
and clinical practices of the study hospital, it was estimated
that the implementation of a protocol for the use of COS PIVCs
in catheterizations lasting >72 h with replacement every 144 h
would save V88,605.24/year in the cost of devices, and up to
V274,714.27/year in total intravenous therapy costs. Likewise,
it was estimated that the use of MOS PIVCs in catheterizations
lasting 72 h with replacement every 96 h would decrease
costs by V80,104.87 and V511,542.78, respectively.
Discussion
This study shows the clear superiority of COS PIVCs over MOS
PIVCs. Indwell times were significantly longer for COS PIVCs,
and phlebitis and infiltration rates were significantly lower,
with an RRR for CRI, for only V0.09/day.
Colonization rates of properly disinfected access ports did
not show significant differences,26 despite reports by other
authors.14 A previous study found that the use of needleless
connectors showed a reduction in the CRI rate, but this did not
reach statistical significance.13 No other authors have found
these results when comparing needleless connectors with
three-way ‘stopcocks’ in central venous catheters.27 On the
other hand, although it has been reported that a dwell time of
more than 72 h increases the risk of S. aureus bacteraemia,28,29
this survey showed that only 9.5% of CRI were caused by
Table I
Insertion success, utility and catheter withdrawal for intention-to-treat population
Assigned system P-value
Closed Open
No. of cases % No. of cases %
Insertion parameters
Successful insertion Yes 529 95.0 563 98.1 0.004
No 28 5.0 11 1.9
Successful puncture First 363 66.0 437 76.3 0.001
Second 129 23.5 99 17.3
Third 58 10.5 37 6.5
Reason why procedure unsuccessful Vasculature anatomy 3 30.0 4 44.4 0.041
Absence of blood reflux 0 0.0 0 0.0
Difficulty advancing catheter 5 50.0 0 0.0
Kinking 0 0.0 0 0.0
Other 2 20.0 5 55.6
Nurse assessment of difficulty of catheter puncture 1 Minimum 242 41.8 262 44.5 0.180
2 171 29.5 159 27.0
3 106 18.3 93 15.8
4 44 7.6 45 7.6
5 Maximum 16 2.8 30 5.1
Nurse assessment of difficulty of insertion 1 Minimum 152 26.3 220 37.4 <0.001
2 171 29.5 161 27.4
3 132 22.8 123 20.9
4 70 12.1 58 9.9
5 Maximum 54 9.3 26 4.4
Nurse assessment of difficulty of fixation 1 Minimum 234 41.8 273 46.7 0.266
2 175 31.3 176 30.1
3 100 17.9 94 16.1
4 34 6.1 32 5.5
5 Maximum 17 3.0 9 1.5
Pain felt by patient Visual analogue scale from 0 to 10 0.378
Rupture of vein during procedure Yes 69 12.0 26 4.4 <0.001
Timing of rupture At puncture 18 26.5 9 36.0 0.266
At insertion 50 73.5 16 64.0
Use of catheters
Maintenance fluids 159 27.0 186 31.1 0.138
Antibiotics 354 63.0 380 64.7 0.538
Chemotherapy 0 0.0 1 0.2 0.322
Lipids 23 4.1 18 3.1 0.349
Transfusions 14 2.5 25 4.3 0.098
Blood draws 68 12.1 72 12.3 0.931
Catheter withdrawal
Success
End of treatment 98 16.8 81 13.5 0.118
Patient discharge 162 27.7 135 22.5 0.039
Lost catheters
Insertion unsuccessful 28 4.8 11 1.8 0.004
Accidental loss of intravenous line 65 11.1 61 10.2 0.598
Study losses
Transfer of patient 18 3.1 19 3.2 0.929
Catheter-related complications
Catheter occlusion 42 7.2 51 8.5 0.398
Infiltration/extravasation 123 21.1 151 25.2 0.091
Phlebitis 70 12.0 101 16.9 0.017
Persistent pain 46 7.9 55 9.2 0.422
Painful haematoma 6 1.0 11 1.8 0.242
Catheter-related infection suspected 13 2.2 11 1.8 0.635
Total catheters removed because of complications 248 42.6 306 51.1 0.004
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Table II
Indwell time analysis for intention-to-treat (ITT) and modified ITT populations
Assigned system Event median ITT (N ¼ 1183) Event median modified ITT (N ¼ 952) Interquartile range (N ¼ 952)
Survival (h) SE 95% CI Survival (h) SE 95% CI Closeda Openb
Closed 137.0 8.7 120.1e154.0 144.5 10.8 123.4e165.6 25 48.50 44.50
Open 96.0 4.3 87.5e104.5 99.0 6.0 87.2e110.8 50 79.00 70.25
Total 114.3 6.0 102.6e126.0 125.0 6.8 111.7e138.3 75 141.75 116.92
P ¼ 0.003 P < 0.001 P ¼ 0.016
SE, standard error; CI, confidence interval.
a Range: 24e972.
b Range: 24e602.
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catheters in non-ICU settings (i.e. on hospital wards).30,31
However, in light of the current economic crisis, the main
finding of this study was the identification of indwell times for
safe and effective routine replacement of PIVCs, thus saving on
consumption and costs. Furthermore, passive safety devices
have 100% effectiveness in eliminating needlestick injuries.
Study limitations
The first limitation of this study was the impossibility of
blinding due to the obvious differences in the two device types.Time
(h) 0 24 48 72 96
Closed N 584 464 352 262 201(SE)*
(SE)*
(1.1%) (1.8%) (2.1%) (2.4%
Open N 599 493 344 237 172(1.0%) (1.9%) (2.3%) (2.4%
*SE, standard error.
Cumulative
survival 
_+ Closed system 
_+ Open system
Time
H
1,0
0,8
0,6
0,4
0,2
0,0
0 24 48 72 96 12
0.7
Figure 2. KaplaneMeier survival curve to the onset of complications
interval.Nevertheless, microbiological analysis was blinded. Secondly,
variability in the experience and technique of nurses was
addressed through intensive training before they joined the
research team, although this measure could not eliminate the
unsuccessful insertion of COS PIVCs (5% vs 1.9%; P¼ 0.004). This
limitation actually penalized the COS group. In fact, the cost of
COS PIVCs may be even lower once overcome by the learning
curve. Thirdly, COS and MOS PIVCs are made of different ma-
terials. However, this has little relevance in this study as the
two types of PIVCs that were available at the study hospital at
the beginning of the study were compared (a closed and inte-
grated system with a polyurethane cannula and an open system120 144 168 192 216 240
155 110 88 63 51 41
) (2.6%) (2.7%) (2.8%) (2.9%) (3.0%) (3.0%)
117 82 67 52 45 42
) (2.5%) (2.6%) (2.6%) (2.6%) (2.6%) (2.6%)
 (h)
R
0 144 168 192 216 240
95% CI P
46 0.631 0.883 0.001
(intention-to-treat population). HR, hazard ratio; CI, confidence
0.1 1 10
Log HR
HR 95%CI
0.883 0.631–0.746
0.943 0.577–0.738
0.949 0.598–0.753
0.809 0.474–0.619
1.051 0.682–0.846
1.003 0.624–0.792
0.919 0.570–0.724
1.422 0.715–1.008
0.825 0.561–0.680
0.967 0.488–0.687
0.928 0.630–0.765
0.897 0.555–0.706
1.014 0.631–0.800
0.901 0.585–0.726
1.023 0.599–0.783
1.945 0.332–0.803
0.882 0.626–0.743
3.610 0.204–0.857
1.227 0.665–0.903
0.839 0.559–0.685
Data expressed as Hazard Ratio (Cox model) and error lines are 95% confidence interval.
In favour of Closed system
(COS)
Against Closed system
(COS)
Global
Period 1
Period 2
Medical patient
Surgical patient
Man
Woman
Obese
Non-obese
Diabetic
Non-diabetic
Healthy vascular bed 
Unhealthy vascular bed 
Antibiotic
No antibiotic 
TPN
No TPN
18 G
20 G
22 G
Figure 3. Stratified analysis of the main effect of catheter-related complications in categories of baseline variables. HR, hazard ratio; CI,
confidence interval; TPN, total parenteral nutrition.
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were only replaced when clinically indicated (patient
discharge, in-hospital end of treatment, catheter-related
complication or death). The dwell times of these different
types of PIVCs (which are used in clinical practice around the
world) were studied for complications associated with
extended periods of use. Lastly, blood cultures to confirm
CRBSI were not performed as this would have required a much
larger sample.
On the other hand, although it has been shown that poly-
urethane decreases the risk of phlebitis,7,32,33 Maki andTable III
Rates of catheter-related complications (intention-to-treat population
Catheter-related
complication
Closed system
Rate per 1000
catheter-hours
Rate per 1000
catheter-days
Ra
ca
Hours/catheter 54,173
Days/catheter 2257
Occlusion 0.75 18.61
Infiltration/extravasation 2.27 54.49
Phlebitis grade 2
or higher
1.29 31.01
Persistent pain 0.85 20.38
Painful haematoma 0.11 2.66
Catheter-related infection 0.24 5.76
Total complications 4.58 109.87
CI, confidence interval.
a Compare rates per 1000 catheter-hours.Ringer7 found a trend in CRBSI that was somewhat higher in the
Vialon group than in the Teflon group, without achieving sta-
tistical significance, in contrast to the results of the present
study.
Clinical and economic implications
Increased dwell times without increased risks have impor-
tant implications for PIVC-replacement protocols, such as
catheter removal every 72 h, which is the current practice in
the study hospital and in the majority of hospitals, despite the)
Open system Rate
ratioa
95% CI P-valuea
te per 1000
theter-hours
Rate per 1000
catheter-days
50,296
2096
1.01 22.59 0.76 0.50e1.17 0.199
3.00 66.90 0.76 0.59e0.97 0.021
2.01 44.75 0.64 0.47e0.88 0.004
1.09 24.37 0.78 0.51e1.17 0.210
0.22 4.87 0.51 0.15e1.49 0.183
0.30 6.65 0.80 0.35e1.81 0.572
6.08 135.57 0.75 0.63e0.89 <0.001
Table IV
Cost analysis (intention-to-treat population)
Closed systema
(N ¼ 584)
Open systemb
(N ¼ 599)
Unit cost (V) Total cost (V) Unit cost (V) Total cost (V)
Concept
Closed system with two needleless
connectors
3.495 2041.08 e e
Safety PIVC e e 0.925 554.08
Stopcock e e 0.396 394.02
Luer/luer-lock cap e e 0.042 220.08
Cost of system 3.495 2041.08 1.363 1168.18
Non-sterile gloves 0.032 18.69 0.032 19.17
Sterile gauze 0.090 52.56 0.090 53.91
Transparent dressing 0.434 377.41 0.434 386.96
Infusion line 0.163 117.69 0.163 126.65
Flushing catheter 0.275 1284.80 0.275 1317.80
Nursing time (20 min) 6.347 3706.65 6.347 3801.85
Total study costc 10.836 7598.88 8.704 6874.52
Cost/day (V) 3.37 3.28
PIVC, peripheral intravenous catheter.
Savings by protocol change:
 In 2012, the Hospital Clı´nico ‘San Carlos’ used 230,475 PIVCs using a protocol of replacing catheters every 72 h, extended to 96 h for
closed systems (Nexiva).
 Of all catheters, 25% [57,619 PIVCsd 16% lost catheters (see Table I)  96 h ¼ 4,646,400 catheter-hours] were long term (>72 h) and
75% [172,856 PIVCs d 12% lost catheters (see Table I)  72 h ¼ 10,952,136 catheter-hours] were short term (72 h).
 Applying a simple calculation, one can determine how many Nexiva could be saved in catheterizations >72 h with a change protocol
every 144 h, and the number of open catheters that could be saved in catheterizations 72 h with a change protocol every 96 h:
 Closed system: 4,646,400 catheter-hours/144 h ¼ 32,267 catheters.
57,619 e 32,267 ¼ 25,352 PIVCs saved  V3.495 ¼ V88,605.24/year saving in cost of devices. Also 25,352 PIVCs saved  V10.836
¼ V274,714.27/year saving in intravenous therapy costs.
 Open system: 10,952,136 catheter-hours/96 h ¼ 114,085 catheters.
172,856e 114,085¼ 58,771 PIVCs savedV1.363¼V80,104.87/year saving in cost of devices. Also 58,771 PIVCs savedV8.704
¼ V511,542.78/year saving in intravenous therapy costs.
a Catheterization-days: 2257.2.
b Catheterization-days: 2095.7.
c All prices paid by hospital in 2012 (VAT included).
J.L. Gonza´lez Lo´pez et al. / Journal of Hospital Infection 86 (2014) 117e126124fact that phlebitis was not observed on the third day in>90% of
COS PIVCs and 86% of MOS PIVCs.
Although the duration of catheterization has been consid-
ered to be the most important predictor of phlebitis,7,10,28 and
has led to worldwide protocols of routine resiting every
48e96 h, this recommendation has been questioned because
the evidence suggests that the risk of complications, especially
phlebitis, increases until approximately 48 h but then remains
more or less constant until the sixth day (144 h).8,10
The 2011 guidelines of the CDC34 recommending catheter
removal at 72e96 h are based on three relatively dated
studies.7,12,28 In the most recent of these studies, Lai recom-
mended prolonging the indwell time from 72 to 96 h, with a
saving of US$61,200/year for a hospital with 375 beds.12 How-
ever, this study had important limitations; it was non-
randomized, there were no cultures of catheter tips, and
the sample size of catheters lasting >96 h was very small
(N ¼ 32). The present study showed that COS PIVCs had a
probability of phlebitis-free survival of 80.4% at 144 h. The
probability of survival of MOS PIVCs to 96 h (79.9%) confirms,
with an adequate sample size, the safety of prolonging the
dwell time of PIVCs, even with Teflon cannulae, up to 96 h, as
suggested by Lai.12Using the ‘San Carlos’ Hospital perspective, the application
of these findings to clinical practice may involve savings in
intravenous therapy of up toV786,257.05/year/1000 beds with
no increase in risk.
Other studies have shown that catheter replacement only
when clinically indicated is a safe strategy35,36 and reduces
costs.35 A 2010 Cochrane review concluded that clinical
management could be as effective as scheduled catheter
exchange.37 Recently, Rickard et al.38 tested whether the
policy of routine replacement after a set dwell time reduces
complications vs replacement purely on clinical grounds. In
their study, the mean dwell time was 99 h when catheters
were replaced when clinically indicated but only 70 h when
replaced routinely. This study, unlike the present study, was
not testing catheter dwell times per se. In the present study,
the mean indwell time for the total sample was 206.4 h,
which is more than double the mean indwell time reported by
Rickard et al. but proves similar points, namely that routine
replacement does not reduce complications but causes many
unnecessary invasive procedures, and that costs can be driven
down without compromising on patient outcomes by allowing
the catheter to remain in place for as long as clinically
indicated.
J.L. Gonza´lez Lo´pez et al. / Journal of Hospital Infection 86 (2014) 117e126 125Finally, recommendations for optimal dwell times of PIVCs
should be re-evaluated, and may differ depending on whether
a COS or MOS device is being used. The implementation of a
protocol to use COS PIVCs in catheterizations that are expected
to remain in place for >72 h, with replacement every 144 h,
and MOS PIVCs in catheterizations expected to remain in place
for 72 h, with replacement every 96 h, will significantly
reduce the cost of intravenous therapy without increasing the
risk. This constitutes good news, from a clinical, economic and
environmental point of view, for healthcare systems. It reduces
risks and discomfort to patients, while decreasing intravenous
therapy costs and biohazard waste.
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